Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bagust

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
QJM : Monthly Journal of the Association of Physicians|April 1, 1997
Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patientsB M Hendry, G C Viberti, S Hummel, et al.
Archives of Disease in Childhood|November 29, 2002
Economic evaluation of an acute paediatric hospital at home clinical trialA Bagust, A Haycox, S A Sartain, et al.
Pharmacoeconomics|July 6, 1997
An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United KingdomS Hummel, J Piercy, R Wright, et al.
Health Technology Assessment (Winchester, England)|October 7, 2009
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphomaA Boland, A Bagust, J Hockenhull, et al.
Health Technology Assessment (Winchester, England)|June 24, 2010
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapyC Martin Saborido, J Hockenhull, A Bagust, et al.
Heart (British Cardiac Society)|April 16, 2005
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility studyA Bagust, A D Grayson, N D Palmer, et al.
Health Technology Assessment (Winchester, England)|July 2, 2009
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphomaY Dundar, A Bagust, J Hounsome, et al.
Health Technology Assessment (Winchester, England)|October 23, 2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neckJ Greenhalgh, A Bagust, A Boland, et al.
The International Journal of Health Planning and Management|January 1, 1993
Dissecting the patient stay in the UKP C Richardson, D E Barwick, A Bagust, et al.
Health Technology Assessment (Winchester, England)|May 30, 2003
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluationA Boland, Y Dundar, A Bagust, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
QJM : Monthly Journal of the Association of Physicians|April 1, 1997
Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patientsB M Hendry, G C Viberti, S Hummel, et al.
Archives of Disease in Childhood|November 29, 2002
Economic evaluation of an acute paediatric hospital at home clinical trialA Bagust, A Haycox, S A Sartain, et al.
Pharmacoeconomics|July 6, 1997
An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United KingdomS Hummel, J Piercy, R Wright, et al.
Health Technology Assessment (Winchester, England)|October 7, 2009
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphomaA Boland, A Bagust, J Hockenhull, et al.
Health Technology Assessment (Winchester, England)|June 24, 2010
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapyC Martin Saborido, J Hockenhull, A Bagust, et al.
Heart (British Cardiac Society)|April 16, 2005
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility studyA Bagust, A D Grayson, N D Palmer, et al.
Health Technology Assessment (Winchester, England)|July 2, 2009
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphomaY Dundar, A Bagust, J Hounsome, et al.
Health Technology Assessment (Winchester, England)|October 23, 2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neckJ Greenhalgh, A Bagust, A Boland, et al.
The International Journal of Health Planning and Management|January 1, 1993
Dissecting the patient stay in the UKP C Richardson, D E Barwick, A Bagust, et al.
Health Technology Assessment (Winchester, England)|May 30, 2003
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluationA Boland, Y Dundar, A Bagust, et al.
Pageof 6